Pemvidutide

Overview

Pemvidutide, also known by the development code ALT-801, is an investigational peptide being developed by Altimmune. It belongs to a class of agents designed to act on more than one metabolic target simultaneously. Specifically, it is a dual agonist intended to engage both the GLP-1 receptor and the glucagon receptor in a single molecule.

The main conditions under investigation for pemvidutide are obesity and metabolic dysfunction-associated steatohepatitis, often abbreviated MASH (a serious form of fatty liver disease, formerly referred to as NASH). The combination of weight-related and liver-related targets reflects growing interest in therapies that address overlapping metabolic problems.

As with other compounds in this section, pemvidutide is experimental. It has not received regulatory approval for any indication, and the information here describes a candidate still progressing through clinical development rather than an established treatment.

How it works

Pemvidutide is engineered to activate two receptors: the GLP-1 receptor and the glucagon receptor. GLP-1 signaling is associated with reduced appetite, increased satiety, and favorable effects on glucose handling. Glucagon receptor activation is of particular interest because it can increase energy expenditure and influence fat metabolism in the liver.

The rationale for combining these two actions is that GLP-1 helps reduce food intake while glucagon signaling may boost the body's energy use and promote mobilization of liver fat. In conditions like MASH, where excess fat accumulates in the liver and drives inflammation, a mechanism that targets liver fat directly is especially appealing.

Balancing these two activities is a central design challenge, since glucagon also affects blood sugar. Developers aim to tune the molecule so the combined effect favors weight loss and improved liver health while maintaining acceptable metabolic control. The real-world balance of these effects is what clinical trials are designed to clarify.

Research & evidence

Pemvidutide has been studied in clinical trials targeting both obesity and MASH. Altimmune has advanced dedicated trial programs in these areas, reflecting a strategy of pursuing two related but distinct metabolic indications with the same molecule. The liver-focused work is of particular interest given the limited number of approved options for advanced fatty liver disease.

Reported early and mid-stage findings have generated interest in the candidate's potential effects on body weight and on markers relevant to liver health. As an investigational agent, however, its place in treatment remains unproven, and outcomes from larger, longer, and confirmatory trials are needed before any definitive judgments can be made.

This encyclopedia does not cite specific efficacy percentages, participant counts, or trial dates, as these details are best obtained from primary sources and evolve over time. The balanced takeaway is that pemvidutide is an actively investigated dual agonist with a plausible mechanism for obesity and MASH, still requiring confirmation.

Safety & legal status

The safety profile of pemvidutide is still being characterized through ongoing research. As a GLP-1-containing dual agonist, gastrointestinal effects such as nausea are commonly seen across this drug class, and the glucagon component introduces additional considerations related to metabolism that trials are designed to monitor. Only completed studies can define its specific risk profile.

Pemvidutide is not approved by regulatory authorities for obesity, MASH, or any other condition. It is available only within the framework of authorized clinical trials and is not a marketed medicine or a consumer supplement. Any product offered for sale as pemvidutide outside of formal research should be regarded as unregulated and potentially unsafe.

This encyclopedia provides no dosing guidance. Individuals interested in clinical trials should seek information through legitimate medical channels and discuss eligibility and risks with qualified healthcare professionals rather than attempting to access investigational compounds independently.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Noureddin M, Harrison SA, Loomba R, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. 2025. Peer-reviewed study
2. Tacke F. The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial. Lancet. 2025. Peer-reviewed study
3. Browne SK, Suschak JJ, Tomah S, et al. Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. JHEP Rep. 2025. Peer-reviewed study
4. Rajab I, Emara A, Rakab MS, et al. Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials. Naunyn Schmiedebergs Arch Pharmacol. 2026. Peer-reviewed study
5. Harrison SA, Browne SK, Suschak JJ, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol. 2025. Peer-reviewed study